Tectonic's TX2100 Shows Favorable Phase 1a Safety, Wins FDA Fast Track for HHT
TECX sits 61% above its 52-week low of $14.6.
Summary
Tectonic announced on September 29, 2026 favorable Phase 1a results for TX2100, its VHH-Fc fusion antagonist antibody targeting the APJ (apelin) receptor for hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder with no approved therapies. The drug was safe and well-tolerated across all six dose cohorts in a randomized, double-blind, placebo-controlled, single ascending dose, first-in-human trial in 48 healthy adult volunteers (men and women of non-childbearing potential, ages 18–55), with no serious adverse events, and PK data confirmed target engagement. The FDA granted Fast Track Designation in September 2026 and cleared the IND in August 2026 for a Phase 1b trial in HHT patients. The company plans to start Phase 1b by year-end 2026 and Phase 2 in early 2027. This is a meaningful de-risking event for a lead asset in a high-unmet-need indication, and the stock is likely to react positively.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Tectonic announced favorable Phase 1a safety, tolerability and PK results for TX2100, FDA Fast Track designation, and IND clearance for the Phase 1b trial in HHT on September 29, 2026.
- Phase 1a Results — Treatment-emergent adverse events were mild or moderate and transient; no deaths or severe treatment-emergent adverse events occurred; no clinically significant changes in vital signs, lab assessments or ECGs. PK results reflected target-mediated drug disposition at low concentrations and support once weekly and every other week subcutaneous dosing regimens.
- Phase 1a Design
- Phase 1a results were in healthy adult volunteers (men and women of non-childbearing potential, ages 18–55).
- Phase 1a doses were administered intravenously and subcutaneously.
- Phase 1a clinical trial was a randomized, double-blind, placebo-controlled, single ascending dose (SAD), first-in-human trial.
- Phase 1a enrolled 48 healthy adult volunteers (men and women of non-childbearing potential, ages 18–55) across six sequential dose cohorts of eight participants each, randomized 3:1 to receive a single dose of TX2100 or matching placebo.
- Phase 1a dose cohorts: Cohort A, 0.1 mg/kg IV; Cohort B, 0.3 mg/kg IV; Cohort C, 100 mg SC; Cohort D, 1 mg/kg IV; Cohort E, 300 mg SC; Cohort F, 600 mg SC.
- Part B of Phase 1a, a multiple dose cohort, has completed enrollment with six healthy volunteers.
- Part B dosing regimen: 600 mg SC on Day 1, followed by 200 mg SC dose on Day 8 and 200 mg SC dose on Day 15.
- Part B of the Phase 1a trial is an open-label design.
- Dose Selection — Dose selection for Phase 1b and Phase 2 was informed by two independent methods: exposures associated with high receptor occupancy inferred from observed TMDD, and target exposure levels shown to drive activity in nonclinical models of HHT.
- Phase 1b Trial — Phase 1b trial will be open-label in patients with hematologic-support dependent HHT, with endpoints including need for iron/red blood cell support and hematologic parameters.
- Phase 2 Trial — Phase 2 trial will run in parallel in patients with moderate-to-severe HHT and will be placebo-controlled, with endpoints including epistaxis and hemoglobin, and expected to include hematologic support and other endpoints relevant to HHT.
- Regulatory — FDA cleared the IND application in August 2026 and granted TX2100 Fast Track Designation for the treatment of HHT in September 2026.
- Upcoming Data — Anti-drug antibody (ADA) results are pending. Detailed results from the TX2100 Phase 1a clinical trial, including safety, tolerability, PK and ADA results, will be presented at the CureHHT 16th HHT International Scientific Conference, taking place October 12-16, 2026.
All 28 details
- TX2100 is a VHH-Fc fusion antagonist antibody targeting the APJ (apelin) receptor.
- Phase 1a results were in healthy adult volunteers (men and women of non-childbearing potential, ages 18–55).
- Phase 1b trial will be open-label in patients with hematologic-support dependent HHT.
- Phase 2 trial will run in parallel in patients with moderate-to-severe HHT.
- Phase 1a doses were administered intravenously and subcutaneously.
- Treatment-emergent adverse events were mild or moderate and transient.
- No deaths or severe treatment-emergent adverse events occurred.
- No clinically significant changes in vital signs, lab assessments or ECGs.
- Anti-drug antibody (ADA) results are pending.
- PK results reflected target-mediated drug disposition (TMDD) at low concentrations.
- Dose selection for Phase 1b and Phase 2 was informed by two independent methods: exposures associated with high receptor occupancy inferred from observed TMDD, and target exposure levels shown to drive activity in nonclinical models of HHT.
- Observed PK results support once weekly and every other week subcutaneous dosing regimens.
- Phase 1b endpoints include need for iron/red blood cell support and hematologic parameters.
- Phase 2 trial will be placebo-controlled with endpoints including epistaxis and hemoglobin.
- FDA cleared the IND application in August 2026.
- FDA granted TX2100 Fast Track Designation for the treatment of HHT in September 2026.
- Phase 1a clinical trial was a randomized, double-blind, placebo-controlled, single ascending dose (SAD), first-in-human trial.
- Phase 1a enrolled 48 healthy adult volunteers (men and women of non-childbearing potential, ages 18–55) across six sequential dose cohorts of eight participants each, randomized 3:1 to receive a single dose of TX2100 or matching placebo.
- Phase 1a dose cohorts: Cohort A, 0.1 mg/kg IV; Cohort B, 0.3 mg/kg IV; Cohort C, 100 mg SC; Cohort D, 1 mg/kg IV; Cohort E, 300 mg SC; Cohort F, 600 mg SC.
- Part B of Phase 1a, a multiple dose cohort, has completed enrollment with six healthy volunteers.
- Part B dosing regimen: 600 mg SC on Day 1, followed by 200 mg SC dose on Day 8 and 200 mg SC dose on Day 15.
- Detailed results from the TX2100 Phase 1a clinical trial, including safety, tolerability, PK and ADA results, will be presented at the CureHHT 16th HHT International Scientific Conference, taking place October 12-16, 2026.
- Part B of the Phase 1a trial is an open-label design.
- The Phase 1a trial was conducted at CMAX Clinical Research in Adelaide, South Australia.
- The Phase 1a trial has an ANZCTR registration number ACTRN12626000242325.
- Phase 2 trial endpoints expected to include epistaxis, hemoglobin, hematologic support, and other endpoints relevant to HHT.
- Phase 1a primary objectives: characterize safety and tolerability, assessed by incidence of AEs and SAEs, and clinically significant changes in safety laboratory parameters, 12-lead ECGs, and vital signs.
- Phase 1a key secondary objective: characterize pharmacokinetic profile of TX2100; immunogenicity also assessed.
At the time of this announcement, TECX was trading at $23.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $459.6M. The 52-week trading range was $14.60 to $39.53. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.